Adipose tissue dysfunction and hypertriglyceridemia: Mechanisms and management

Obesity Reviews

Volumn 12, Issue 10, 2011, Pages 829-840

  van de Woestijne, A P ^a   Monajemi, H ^a   Kalkhoven, E ^a,b   Visseren, F L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Netherlands Metabolomics Center   (Netherlands)

Author keywords

Adipose tissue; Atherosclerosis; Obesity; Triglycerides

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; CORTICOSTEROID; ESTROGEN; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; LIPOPROTEIN LIPASE; NICOTINIC ACID; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PROTEINASE INHIBITOR; RETINOID DERIVATIVE; ROSIGLITAZONE; TAMOXIFEN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG POTENCY; FLUID RETENTION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; OBESITY; PANDEMIC; PATHOPHYSIOLOGY; RISK REDUCTION; SIDE EFFECT; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; HUMANS; HYPERTRIGLYCERIDEMIA;

EID: 80053130721     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00900.x     Document Type: Article

References (101)

1. Moreton JR. Atherosclerosis and alimentary hyperlipemia. Science 1947; 106: 190-191.
2. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.
3. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G etal. Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110: 2678-2686.
4. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S etal. Triglycerides and the risk of coronary heart disease: 10158 incident cases among 262525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-458.
5. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
6. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316.
7. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and the risk of stroke in the general population. JAMA 2008; 300: 2142-2152.
8. Simha V, Garg A. Inherited lipodystrophies and hypertriglyceridemia. Curr Opin Lipidol 2009; 20: 300-308.
9. Chehab FF. Obesity and lipodystrophy - where do the circles intersect? Endocrinology 2008; 149: 925-934.
10. Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F etal. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010; 211: 1-8.
11. Zhang X, Qi R, Xian X, Yang F, Blackstein M, Deng X etal. Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ Res 2008; 102: 250-256.
12. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176: 1113-1120.
13. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009; 10: 109-121.
14. Tchoukalova YD, Votruba SB, Tchkonia T, Giorgadze N, Kirkland JL, Jensen MD. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A 2010; 107: 18226-18231.
15. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
16. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11: 525-531.
17. Trayhurn P, Wang IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
18. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr 2008; 100: 227-235.
19. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K etal. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911.
20. 2-regulated gene expression. FASEB J 2002; 16: 1151-1162.
21. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007; 455: 479-492.
22. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE etal. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009; 58: 718-725.
23. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.
24. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K etal. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
25. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E etal. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461.
26. Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T etal. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009; 119: 1201-1215.
27. Sharma NK, Das SK, Mondal AK, Hackney OG, Chu WS, Kern PA etal. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab 2008; 93: 4532-4541.
28. Boden G, Duan X, Homko C, Molina EJ, Song W, Perez O etal. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008; 57: 2438-2444.
29. Xue X, Piao JH, Nakajima A, Sakon-Komazawa S, Kojima Y, Mori K etal. Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem 2005; 280: 33917-33925.
30. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A etal. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-35292.
31. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
32. Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 2006; 341: 507-514.
33. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol 2009; 29: 1944-1949.
34. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S etal. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011; 121: 1858-1870.
35. Skurk T, Berti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
36. Satoh N, Shimatsu A, Himeno A, Sasaki Y, Yamakage H, Yamada K etal. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010; 33: e7.
37. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
38. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-184.
39. Bourlier V, Zakaroff-Girard A, Miranville A, De BS, Maumus M, Sengenes C etal. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 2008; 117: 806-815.
40. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
41. Lass A, Zimmermann R, Oberer M, Zechner R. Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog Lipid Res 2011; 50: 14-27.
42. Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res 2007; 48: 2547-2559.
43. Kolditz CI, Langin D. Adipose tissue lipolysis. Curr Opin Clin Nutr Metab Care 2010; 13: 377-381.
44. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunction linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 367-377.
45. Bezaire V, Mairal A, Anesia R, Lefort C, Langin D. Chronic TNFalpha and cAMP pre-treatment of human adipocytes alter HSL, ATGL and perilipin to regulate basal and stimulated lipolysis. FEBS Lett 2009; 583: 3045-3049.
46. Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity. Am J Physiol 1994; 266: E600-E605.
47. Kim SK, Kim HJ, Ahn CW, Park SW, Cho YW, Lim SK etal. Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in type 2 diabetic patients. Endocr J 2008; 55: 1085-1092.
48. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 2007; 18: 263-270.
49. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54: 795-802.
50. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010; 375: 2267-2277.
51. Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor α induced insulin resistance. J Biol Chem 2007; 282: 7783-7789.
52. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009; 42: 1331-1346.
53. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002; 51: 1319-1336.
54. Sharma AM, Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-395.
55. Adiels M, Boren J, Caslake MJ, Soro A, Westerbacka J, Wennberg B etal. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25: 1697-1703.
56. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 2007; 48: 1336-1342.
57. Potts JL, Coppack SW, Fisher RM, Humphreys SM, Gibbons GF, Frayn KN. Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects. Am J Physiol 1995; 268: E588-E594.
58. Mitrou P, Boutati E, Lambadiari V, Maratou E, Komesidou V, Papakonstantinou A etal. Rates of lipid fluxes in adipose tissue in vivo after a mixed meal in morbid obesity. Int J Obes (Lond) 2010; 34: 770-774.
59. Sadur CN, Yost TJ, Eckel RH. Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 1984; 59: 1176-1182.
60. Panarotto D, Remillard P, Bouffard L, Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002; 32: 84-92.
61. Tan GD, Olivecrona G, Vidal H, Frayn KN, Karpe F. Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone. Diabetologia 2006; 49: 2412-2418.
62. Ardilouze JL, Fielding BA, Currie JM, Frayn KN, Karpe F. Nitric oxide and beta-adrenergic stimulation are major regulators of preprandial and postprandial subcutaneous adipose tissue blood flow in humans. Circulation 2004; 109: 47-52.
63. Karpe F, Fielding BA, Ardilouze JL, Ilic V, Macdonald IA, Frayn KN. Effects of insulin on adipose tissue blood flow in man. J Physiol 2002; 540: 1087-1093.
64. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002; 51: 2467-2473.
65. Samra JS, Simpson EJ, Clark ML, Forster CD, Humphreys SM, Macdonald IA etal. Effects of epinephrine infusion on adipose tissue: interactions between blood flow and lipid metabolism. Am J Physiol 1996; 271: E834-E839.
66. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363-1379.
67. Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994; 24: 188-194.
68. Radeau T, Malcolm R, Lau P, Borthwick J, McPherson R. Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. Atherosclerosis 1998; 139: 369-376.
69. Zhou H, Li Z, Hojjati MR, Jang D, Beyer TP, Cao G etal. Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism. J Lipid Res 2006; 47: 2011-2019.
70. Ting HJ, Stice JP, Schaff UY, Hui DY, Rutledge JC, Knowlton AA etal. Triglyceride-rich lipoproteins prime aortic endothelium for inflammatory responses to TNF-α. Circ Res 2007; 100: 381-390.
71. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K etal. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008; 118: 731-742.
72. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-687.
73. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J etal. Triglyceride-rich lipoproteins isolated by selected-affinity antiapolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994; 14: 1767-1774.
74. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM etal. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001; 154: 229-236.
75. Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther 2010; 8: 413-423.
76. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA etal. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. J Clin Endocrinol Metab 2006; 91: 973-979.
77. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
78. National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. Clin Chem 1995; 41: 1421-1426.
79. Tziomalos K, Dimitroula HV, Katsiki N, Savopoulos C, Hatzitolios AI. Effects of lifestyle measures, antiobesity agents and bariatric surgery on serological markers of inflammation in obese patients. Mediators Inflamm 2010; DOI: 10.1155/2010/364957
80. Yokoyama H, Emoto M, Araki T, Fujiwara S, Motoyama K, Morioka T etal. Effect of aerobic exercise on plasma adiponectin levels and insulin resistance in type 2 diabetes. Diabetes Care 2004; 27: 1756-1758.
81. McLaughlin T, Abbasi F, Lamendola C, Kim HS, Reaven GM. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. Metabolism 2001; 50: 819-824.
82. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007; 56: 2655-2667.
83. Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology 2007; 132: 2181-2190.
84. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002; 4: 407-414.
85. Aronne LJ, Wadden T, Isoldi KK, Woodworth KA. When prevention fails: obesity treatment strategies. Am J Med 2009; 122: S24-S32.
86. Durstine JL, Grandjean PW, Cox CA, Thompson PD. Lipids, lipoproteins and exercise. J Cardiopulm Rehabil 2002; 22: 385-398.
87. Kraus WE, Houmard JA, Duscha BD. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347: 1483-1492.
88. Andersson K, Karlstrom B, Freden S, Petersson H, Ohrvall M, Zethelius B. A two-year clinical lifestyle intervention program for weight loss in obesity. Food Nutr Res 2008; DOI: 10.3402/fnr.v52i0.165
89. Rosen CJ. Revisiting the rosiglitazone story - lessons learned. N Engl J Med 2010; 363: 803-806.
90. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-1201.
91. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
92. Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010; 9: 347-354.
93. Ferns G, Keti V, Griffin B. Investigation and management of hypertriglyceridemia. J Clin Pathol 2008; 61: 1174-1183.
94. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P etal. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
95. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
96. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ etal. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006; 332: 752-760.
97. Fojo SS, Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 1992; 231: 669-677.
98. Cefalu AB, Noto D, Arpi ML, Yin F, Spina R, Hilden H etal. Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab 2009; 94: 4584-4590.
99. Peterfy M, Ben-Zeev O, Mao HZ, Weissglas-Volkov D, Aouizerat BE, Pullinger CR etal. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet 2007; 39: 1483-1487.
100. Beigneux AP. GPIHBP1 and the processing of triglyceride-rich lipoproteins. Clin Lipidol 2010; 5: 575-582.
101. Calandra S, Priore OC, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol 2006; 17: 122-127.